Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma (Q37815607)

23 August 2017

1 reference

title

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma (English)

1 reference

23 August 2017

1 reference

7

0 references

Viviana Bazan

8

object named as

Viviana Bazan

1 reference

23 August 2017

6

Corrado Ficorella

1 reference

23 August 2017

11

Antonio Russo

1 reference

23 August 2017

9

Giuseppe Colucci

1 reference

23 August 2017

Giuseppe Bronte

1

1 reference

23 August 2017

Sergio Rizzo

2

1 reference

23 August 2017

Laura La Paglia

3

1 reference

23 August 2017

Vincenzo Adamo

4

1 reference

23 August 2017

Sergio Siragusa

5

1 reference

23 August 2017

Nicola Gebbia

10

1 reference

23 August 2017

1 November 2010

1 reference

23 August 2017

Cancer Treatment Reviews

1 reference

23 August 2017

36 Suppl 3

1 reference

23 August 2017

S21-9

1 reference

EGFR antagonists in cancer treatment

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

The epidermal growth factor receptor family

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Structure and clinical relevance of the epidermal growth factor receptor in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

The Ras signal transduction pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

New exchange, new target

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Understanding Ras: 'it ain't over 'til it's over'.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Increasing complexity of the Ras signaling pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Oncogenic Ras and its role in tumor cell invasion and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Targeting the RAF-MEK-ERK pathway in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

PI3K/Akt signalling pathway and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

PTEN: a new guardian of the genome.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Inhibition of EGFR signaling: all mutations are not created equal

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

A mouse model for EML4-ALK-positive lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

EML4-ALK fusion lung cancer: a rare acquired event

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970016-5

7 January 2021

10.1016/S0305-7372(10)70016-5

Identifiers

DOI

1 reference

23 August 2017

1 reference